Last reviewed · How we verify
TURCOVAC
TURCOVAC is a vaccine that works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus.
TURCOVAC is a vaccine that works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus. Used for COVID-19 prevention.
At a glance
| Generic name | TURCOVAC |
|---|---|
| Sponsor | Health Institutes of Turkey |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
TURCOVAC is a recombinant adenovirus vector-based vaccine that encodes for the SARS-CoV-2 spike protein. This protein is recognized by the immune system, which mounts a response to produce antibodies and immune cells that can recognize and target the virus. The vaccine is designed to provide immunity against SARS-CoV-2 infection.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TURCOVAC CI brief — competitive landscape report
- TURCOVAC updates RSS · CI watch RSS
- Health Institutes of Turkey portfolio CI